Public use datasets are available for the 6 clinical trials, Therapeutics for Inpatients with Covid-19 (TICO),
conducted under the ACTIV-3 program;
Click on Request access and complete the contact information and you will receive a username and password that allows access to data from these 6 studies.
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigtational Therapeutics for Hospitalized Patients with COVID-19 (TICO)
The study will evaluate the safety and efficacy of multiple investigational agents intended to enhance the host immune response to SARS-CoV-2 infection, or directly enhance viral control, in order to limit disease progression. Using a master protocol, successive trials with the protocol will be adaptive, randomized, and initially placebo-controlled. All participants will receive standard of care (SOC) treatment. If an investigational agent shows superiority over placebo + SOC as initially defined, SOC for future investigational treatment evaluations will be modified accordingly. The initial investigational agents will be neutralizing monoclonal antibodies.
Protocol Summary
Major Results Publications for TICO Trials